The headline does not buy the medicine
The brand-name programme lists, item by item: a bloodwork charge, a consultation charge to review it, the cost of the pen itself with an approximate duration, and then the monthly programme charge — which the page says covers a monthly check-in appointment, a body-composition assessment and a diet plan.
So the advertised monthly figure is a supervision fee. A first quarter on that programme costs several times it. We have marked that row as excluding medication in the underlying data, so no tool on this site can treat it as a month's supply.
Five programmes, two of them micro-dose
Beside the brand-name lane sit compounded semaglutide and compounded tirzepatide programmes, where the page says the medication is dosed and given to the patient rather than priced separately, and two micro-dose memberships with their milligram bands stated.
The bloodwork and review-consultation charges apply across the programmes, so none of the five published figures is what a first month costs. The dose bands on the micro-dose memberships are a genuine disclosure: they say what strength the membership is for.
Four ways to name the wrong company
This site produced four distinct false-positive shapes for an entity check in one page set: a web agency's footer credit, a defined term from the terms of use, two clinician credentials, and a phrase from a staff biography. Every one looks like a company name to a pattern and none of them is.
Read in context, none is the operator, and no operator is named anywhere. It names no compounding pharmacy, no individual prescribing clinician as such, and no service area.
Infinity Med Spa's published pricing
| Medication | Price | Verified |
|---|---|---|
| Glp-1 (brand) | $395/mo⛔⛔ THE DRUG IS NOT IN THIS FIGURE. The same page states "$1,300 cost of Ozempic pen (pen lasts approximately 12 weeks)", plus $200 bloodwork and $400 for the consultation to review it. The $395 covers a monthly check-in, a body-composition assessment and a diet plan | September 2026source |
| Semaglutide (compounded) | $395/mothe compounded programme, where the page says the medication is dosed and given to the patient rather than priced separately; the $200 bloodwork and $400 review consultation are still charged on top | September 2026source |
| Tirzepatide (compounded) | $595/mothe compounded tirzepatide programme on the same terms, with the same separate bloodwork and consultation charges | September 2026source |
| Semaglutide (compounded) | $195/moa separately named micro-dose membership at a stated dose band | September 2026source |
| Tirzepatide (compounded) | $295/mothe tirzepatide micro-dose membership at a stated dose band | September 2026source |
| Glp-1 (compounded) | $600a fee, not a drug price: $200 for bloodwork plus $400 for the NP or PA consultation to review it, charged before any programme begins | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 198 providers reviewed here are paid partners today; the other 194 are not. See how this works.
See Infinity Med Spa's current price →Good fit if
- Readers who want a brand-name route with the drug cost stated separately and honestly.
- Buyers who want to know exactly what a monthly programme fee buys, item by item.
- People wanting a micro-dose membership with its milligram band stated.
- Anyone who needs a concrete example of a monthly figure that excludes the medication.
Look elsewhere if
- Readers comparing all-in monthly rates; the brand-name headline here is not one.
- Buyers who want a first-month total, since bloodwork and a review consultation are charged on top of every programme.
- Anyone who needs to know which company they are contracting with.
- People who want a named compounding pharmacy or a service-area list.
How this review was verified
- Re-read the priced services page, the about page and a consulting-services page on 7 September 2026, comparing requested to effective URLs and running a nonsense path against the host in the same run, which returned a 404.
- Marked the brand-name row as excluding medication as a declared field, on the strength of the page stating the pen cost separately.
- Recorded the bloodwork and review-consultation charges as a fee row that does not buy medication.
- Read every corporate-suffix match on the host in context and rejected all four shapes — an agency credit, a defined term, two clinician credentials and a biography phrase — rather than naming any of them as the operator.
- Screened the brand against FDA's live warning-letter datatable with a positive control and a nonsense negative control in the same invocation; the single word match returned is an unrelated medical-device company.